» Articles » PMID: 2213510

The Risk of Development of HTLV-I-associated Myelopathy/tropical Spastic Paraparesis Among Persons Infected with HTLV-I

Overview
Date 1990 Jan 1
PMID 2213510
Citations 137
Authors
Affiliations
Soon will be listed here.
Abstract

Using data obtained in national surveys of human T-lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) conducted in Japan in 1987 and 1988, we estimated the yearly and lifetime risk that HAM/TSP will develop in an HTLV-I-infected person. "Definite" HAM/TSP was defined as slowly progressive myelopathy with antibodies to HTLV-I in both serum and cerebrospinal fluid. Estimates of HTLV-I infection rates in eight endemic prefectures, by age group and sex, were obtained from serologic studies of blood donors; population figures, by age group, sex, and prefecture, were obtained from the census. Of 589 definite cases of HAM/TSP reported nationally, 397 occurred in residents of the eight endemic prefectures; of these, 170 reported onset of illness during the years 1982-1988 (average incidence, 24.3 cases/year). Using the estimated HTLV-I infection rates and the 1985 census figures, we estimated the number of HTLV-I-infected persons in the eight prefectures in 1985 at 794,800. We therefore estimated the incidence of HAM/TSP among HTLV-I-infected persons at 3.1 x 10(-5) cases/year; assuming a lifetime of 75 years, the lifetime incidence is approximately one quarter of 1%. This estimate is important in counseling persons such as blood donors found to be infected with HTLV-I.

Citing Articles

Incidence of HTLV-1-associated myelopathy in the UK from 1991 to 2024: a longitudinal observational cohort study.

Rosadas C, Baylon J, Greiller C, Adonis A, Dhasmana D, Davies N Front Med (Lausanne). 2025; 11:1519750.

PMID: 39839639 PMC: 11747315. DOI: 10.3389/fmed.2024.1519750.


Declining trend of HTLV-1 among organ/ tissue donors in Iranian Tissue Bank between 2014-2021.

Letafati A, Mozhgani S, Norouzi M, Aboofazeli A, Taghiabadi Z, Zafarian N Retrovirology. 2024; 21(1):22.

PMID: 39690425 PMC: 11650840. DOI: 10.1186/s12977-024-00656-9.


Complete Rescue of HTLV-1 Infectivity by Depletion of Monocytes Together with NK and CD8 T Cells.

Gutowska A, Sarkis S, Rahman M, Goldfarbmuren K, Moles R, Bissa M Pathogens. 2024; 13(4).

PMID: 38668247 PMC: 11054408. DOI: 10.3390/pathogens13040292.


Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy.

Sato T, Nagai M, Watanabe O, Misu T, Takenouchi N, Ohkubo R J Neurol. 2024; 271(6):3471-3485.

PMID: 38430272 PMC: 11136778. DOI: 10.1007/s00415-024-12239-x.


A Textbook Case of Human T-lymphotropic Virus-1 (HTLV-1)-Induced Adult T-cell Leukemia Treated With Cyclophosphamide, Hydroxydaunorubicin, Oncovin, and Prednisone/Prednisolone (CHOP).

Altaf F, Qureshi Z, Moore S, Golek T, Chawala A Cureus. 2023; 15(11):e49169.

PMID: 38024023 PMC: 10660912. DOI: 10.7759/cureus.49169.